Business
AstraZeneca says its coronavirus vaccine can stop severe disease despite ‘limited’ success against South African variant – ABC News
While the British company says none of more than 2,000 participants died, the trial showed only limited efficacy for the vaccine against mild disease due to the…
British company AstraZeneca says it believes its COVID-19 vaccine developed with Oxford University can protect against severe disease caused by the South African variant of the virus.
Key points:
- Around 2,000 people took part in the trial
- None of the participants were hospitalised or died after receiving the vaccine
- But it showed “limited efficacy” against mild disease due to the South African variant
But AstraZeneca confirmed that early data from a small trial had shown only limited efficacy for…
Continue Reading
-
General24 hours agoAsia stocks plunge, HK suffers steepest fall since 1997
-
General24 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
Business16 hours ago2 Low Cost Active ASX ETFs to consider
-
Business12 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?